Investments Biotech Venture Capital

23 results match your request
Company Activity Date of entrance Business unit
Amakem Healthcare 2011 Biotech Venture Capital Info

Amakem

Founded in 2010, Amakem is an ophthalmology company developing new treatments for serious eye conditions. Amakem’s product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

Amakem is based in Belgium and located in the life sciences incubator “BioVille” at the University of Hasselt. The Company has a long-standing collaboration with the Ophthalmology Research Center of the University Leuven Hospital.
Novate Medical Medical devices 2011 Biotech Venture Capital Info

Novate Medical

Novate Medical, based in Galway Ireland, is focused on developing unique inferior vena cava filter devices (‘IVC filters’) for the prevention of Pulmonary Embolism in patients at transient high risk for Pulmonary Embolism. The lead product is the world’s first, and only, bio-convertible IVC filter. PE is a major cause of acute cardiovascular death in the developed world. It affects over 1.2 million people in the US and Europe annually and may account for as many as 500,000 deaths per year. IVC filters are designed to capture clots, preventing them from reaching the lungs and causing PE.

The Novate device is unique in that it contains a bio-absorbable element that allows for protection during the period of PE risk. It eliminates the need for a second, follow-up procedure which is required to remove currently available temporary IVC filters.
Themis Pharmaceuticals 2011 Biotech Venture Capital Info

Themis

Founded in Vienna in 2009, Themis Bioscience is an Austrian start-up biotechnology company developing novel vaccines against emerging infectious diseases with high unmet medical need. The pre-clinical and clinical development activities focuse on a Dengue and a Chikungunya Fever vaccine. Both vaccine candidates have demonstrated promising preclinical data. They are based on a novel vaccine vector technology that was initially developed at the Institut Pasteur in Paris, with which Themis collaborates.
Cellnovo Medical devices 2011 Biotech Venture Capital Info

Cellnovo

Based in London, Cellnovo develop the first mobile diabetes management system.

The Cellnovo system, developed in-house, is unique in several ways including: the accuracy and size of the pump’s technology, as well as the touch-screen, mobile-connected device that provides healthcare professionals and families immediate access to a myriad of information. Its advanced micropump technology enables people with diabetes to more efficiently manage their life-saving therapies while benefiting from greater personalization and portability.
Complix Pharmaceuticals 2011 Biotech Venture Capital Info

Complix

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a novel class of biopharmaceuticals with distinct structural and functional properties that offer significant advantages over existing protein based therapies. Alphabodies™ bind with high affinity to a wide range of disease targets and are particularly suited to address certain target types that are difficult to access with antibodies or other protein scaffolds.
Arcarios Pharmaceuticals 2010 Biotech Venture Capital Info

Arcarios

Arcarios will focus on the development of novel disease-modifying therapeutics in the field of bone and joint diseases. Its products are aimed at actively restoring bone or joint defects and address a clear unmet medical need. The Company has two early pre-clinical programs. The first product is a small molecule that will be developed for the treatment of osteoarthritis.
The Company’s second program is a therapeutic protein, which will be developed to treat certain bone diseases.

www.arcarios.com
Poxel Pharmaceuticals 2010 Biotech Venture Capital Info

Poxel

Poxel is an innovative new pharmaceuticals company founded in 2009. Its aim is to develop promising compounds in the area of cardio-metabolic diseases – with a primary focus on Type 2 diabetes – up to the stage of phase 2 clinical proof of concept, after which the projects are licensed to pharmaceuticals partners.
Medisse Medical devices 2009 Biotech Venture Capital Info

Medisse

Medisse was established in 2009 and develops resorbable implants based on a flexible material. These implants are intended primarily to prevent adhesions between organs following surgery. The company's unique technology was developed by Twente University in Enschede. First activities to develop this technology were done with the help of BioPartner's First Stage Grant. Medisse is based in Amersfoort and Enschede, the Netherlands.
arGEN-X Pharmaceuticals 2009 Biotech Venture Capital Info

arGEN-X

arGEN-X is a research stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody™ platform. The platform allows arGEN-X to create a wide range of monoclonal antibody leads against a broad range of human disease targets. These antibodies have unique characteristics in terms of affinity and human germline homology, thereby increasing the probability of success later in the drug development path. The company has validated its monoclonal antibody platform on two human disease targets.
ERA Biotech Bioproduction 2009 Biotech Venture Capital Info

ERA Biotech

ERA Biotech is a bioproductivity company; it develops the proprietary Zera® and StorPro® tools that enable the production of difficult to express proteins and improve the performance of cell based factories. Founded in 2002, ERA employs 22 scientists and managers in Barcelona, Spain.
Stentys Medical devices 2009 Biotech Venture Capital Info

Stentys

Stentys was founded in 2006 and intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. Stentys develops a new-generation stent designed for treatment of acute myocardial infarction and coronary artery bifurcations.

Successful IPO in October 2010 : the company raised a total amount of €22.7M.
SpineGuard Medical devices 2009 Biotech Venture Capital Info

SpineGuard

SpineGuard was created in Paris in 2009. The company develops and markets Pediguard, an instrument designed for drilling vertebrae during spine surgery. This is the first wireless device that makes it possible to identify the type of biological tissue with which it is in contact, thanks to the sensor at the end of the instrument. This information is transformed in real time into a sound signal that guides the surgeon throughout the procedure.
FlexGen Laboratories 2009 Biotech Venture Capital Info

FlexGen

FlexGen, created in 2004, is a Dutch company active in the genetic research market. It has developed a patented product, FlexArrayer, for the synthesis of DNA microarrays. The company's unique technology stems from the work of Dutch Space NV and the Leiden University Medical Centre (LUMC) with the help of BioPartner and the Netherlands Genomics Initiative (NGI). FlexGen is working with several customers and leading scientific and industrial partners in order to develop innovative solutions for new-generation sequencing, the validation of biomarkers and other applications.
EyeTechCare Medical devices 2008 Biotech Venture Capital Info

EyeTechCare

EyeTechCare, founded in July 2008 and based near Lyon, has patented an innovative therapy for glaucoma, an eye disease caused by an increase in intraocular pressure affecting the retina and optic nerve. This non-invasive therapy uses high intensity focused ultrasound (HIFU) technology to treat the disease in an outpatient procedure.
EOS imaging Medical devices 2007 Biotech Venture Capital Info

EOS imaging

EOS imaging is specialised in medical imagery applied to orthopaedics. Worldwide, it markets the EOST 2D/3D ultra low-dose medical imaging system, and imaging solution that can generate partial or full-body images of the human body at very low doses of x-rays with a single scan. It is also capable of generating 3-D images of the human skeleton thanks to reconstruction and modelling software based on two simultaneous scans. This solution also makes it possible to provide sets of measurements needed for diagnosis and surgical planning.
CircuLite Medical devices 2007 Biotech Venture Capital Info

CircuLite

CircuLite is a privately held, medical device company developing a unique superficially placed circulatory assist device for the treatment of chronic heart failure. The company’s Synergy™ Pocket Circulatory Assist device is in preclinical studies and the company is preparing for the First in Man implant in 2007. The Synergy device features a micro-pump that is placed superficially in the “pacemaker pocket”. The micropump is minimally invasively connected to the Left Atrium and the Subclavian Artery, and can pump up to 3 liters of blood flow per minute. The minimally invasive placement of the device will allow the transformation of the treatment of chronic heart failure patients from the acute decompensated hospitalized patient to the chronic, ambulatory heart failure patient.
Amsterdam Molecular Therapeutics BV (AMT) Pharmaceuticals 2006 Biotech Venture Capital Info

Amsterdam Molecular Therapeutics BV (AMT)

Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by Scientists at the University of Amsterdam Medical Center in 1998. AMT develops gene-based therapies for orphan ocular and metabolic diseases. Its long-term gene expression technology is based on specific delivery of therapeutic genes into target organs or tissues. AMT floated on the stock market in 2007.
PanGenetics Pharmaceuticals 2006 Biotech Venture Capital Info

PanGenetics

Pangenetics is an antibody development company headquartered in the Netherland that also maintains an office in England. It takes antibodies from the late research phase through to clinical proof of concept. The company employs a lean Sector model with most development activities outsourced.

The company sold one of its anti-NGF antibodies, the PG110, to Abbott for USD 190 million in 2009.
SuperSonic Imagine Medical devices 2006 Biotech Venture Capital Info

SuperSonic Imagine

SuperSonic Imagine is an innovative young company created in 2005 by experts in ultrasound medical imagery, and based in Aix-en-Provence. The new echography developed by SuperSonic Imagine revolutionises medical imagery by making it possible to measure the elasticity of tissues thanks to an innovative process - the analysis of the shear waves generated by its Aixplorer ultrasound system.
SuperSonic Imagine's technology improves the diagnosis of breast cancer by identifying millimetric lesions that cannot be detected by palpation, as well as deep lesions or those in dense breasts that have, until now, been undetectable.
Xention Discovery Ltd Pharmaceuticals 2005 Biotech Venture Capital Info

Xention Discovery Ltd

Xention Discovery Ltd is a drug discovery company that utilizes proprietary technologies to accelerate the development of novel ion channel drugs, overcoming existing limitations in ion channel drug discovery. The company uses true electrophysiological data and ion channel chemoinformatics to support medicinal chemistry and allow the development of drugs that are potent and selective and have preferred functional properties. Xention, which was founded in 2002, is a leader in ion channel drug discovery and has a number of programs in the areas of cardiovascular, neurological and urological disease.